Study of the Effects of STN-DBS on Gait in Parkinson's Disease.

NCT ID: NCT06418802

Last Updated: 2024-05-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-06-30

Study Completion Date

2026-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objectives: Parkinson's disease (PD) is the second most common degenerative disease of the nervous system. Postural instability/gait disorder (PIGD) is one of the motor symptoms of Parkinson's disease, which affects the quality of life of patients with Parkinson's disease. At present, deep brain stimulation(DBS)can significantly improve tremor and bradykinesia, but whether deep brain stimulation is effective for gait disorders is still a controversial topic. In addition, the previous gait assessment mainly focused on scales or simple walking tests, and appropriate and effective evaluation methods are needed to evaluate the efficacy of intervention for gait disorders in PD patients. Therefore, in view of these problems, this study will use wearable devices and traditional scale evaluation to explore the effects of deep brain stimulation on gait in patients with Parkinson's disease.

Methods: A total of 30 patients with Subthalamic nucleus DBS(STN-DBS)were expected to be enrolled. By adjusting the parameters of STN-DBS (voltage, frequency, pulse width), the effects of different parameters on PD gait were compared. Gait changes were mainly analyzed by wearable devices and MDS Unified Parkinson's Disease Rating Scale assessment(MDS-UPDRS). The (Timed Up and Go)TUG test, narrow channel task, circle task and trajectory analysis were performed in the unmedicated state. The wearable device was used to collect the motion information of 10 different positions of the human body, including the wrist, thigh, ankle, foot tip, chest and waist nodes. (1)Experiment 1: Patients were divided into pre-operation group and post-operation group. A case-control study was conducted, and patients were followed up at 1 month,3 months,6 months and 1 year after operation. (2)Experiment 2: This study was a single-center, randomized, double-blind, crossover trial of deep brain stimulation with a short pulse width (30s) versus conventional pulse width (60 s) in PD patients with bilateral STN-DBS. Gait data and MDS-UPDRS were collected at baseline, after 4 weeks and 8 weeks. (3)Experiment 3: By adjusting the frequency parameters of STN-DBS (30,100, and 130HZ), gait data and MDS-UPDRS were collected after 10 minutes of the washout period, and the best DBS parameters for gait improvement were maintained for 4-8 weeks and then evaluated again.

Expected results: By adjusting the parameters (voltage, frequency, and pulse width) of STN-DBS, the potential mechanisms for improving gait disorders in PD were explored, meaningful digital biomarkers for PD gait prognosis were explored, and long-term programming of STN-DBS was guided.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experiment 1: Experimental group 1

PD Patient's gait were followed up at 1 month,3 months,6 months, and 1 year after bilateral STN-DBS surgery.

Group Type EXPERIMENTAL

STN-DBS surgery

Intervention Type PROCEDURE

bilateral subthalamic nucleus deep brain stimulation surgery

Experiment 1: Comparator group 1

PD patient's gait with optimal medical therapy before bilateral STN-DBS surgery.

Group Type ACTIVE_COMPARATOR

STN-DBS surgery

Intervention Type PROCEDURE

bilateral subthalamic nucleus deep brain stimulation surgery

Experiment 2: Experimental group 2

PD patient's gait with a short pulse width (30s) with bilateral STN-DBS.

Group Type EXPERIMENTAL

pulse width

Intervention Type DEVICE

a short pulse width (30s)

Experiment 2: Comparator group 2

PD patient's gait with the conventional pulse width (60 s) with bilateral STN-DBS.

Group Type ACTIVE_COMPARATOR

pulse width

Intervention Type DEVICE

a short pulse width (30s)

Experiment 3: Experimental group 3

PD patient's gait with frequency parameters(60,100, and 130HZ) with bilateral STN-DBS.

Group Type EXPERIMENTAL

frequency

Intervention Type DEVICE

frequency parameters of STN-DBS (60,100, and 130HZ)

Experiment 3: Comparator group 3

PD patient's gait with the conventional frequency parameters with bilateral STN-DBS.

Group Type ACTIVE_COMPARATOR

frequency

Intervention Type DEVICE

frequency parameters of STN-DBS (60,100, and 130HZ)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

STN-DBS surgery

bilateral subthalamic nucleus deep brain stimulation surgery

Intervention Type PROCEDURE

pulse width

a short pulse width (30s)

Intervention Type DEVICE

frequency

frequency parameters of STN-DBS (60,100, and 130HZ)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (1) Age 40-75 years old; (2) Patients who meet the Chinese Parkinson's disease diagnostic criteria and confirmed by two high-level physicians (\>10 years); (3) Diagnosed by Parkinson's Specialty Clinic For Parkinson's disease for more than 1 year and have been effective after treatment; (4) Hearing, visual and cognitive abilities are normal; (5) The subjects were informed of the test purpose, the benefits of the test, the test process and possible unexpected situations before the test , and signed the trial informed consent form.

Exclusion Criteria

* (1) A variety of secondary Parkinson's syndrome (including traumatic, drug-induced, tumor, vascular, toxic, hydrocephalus, etc.) and Parkinson's superimposed syndrome. (2) Other diseases that cause gait disorders, including spinal joint injuries, muscle spasm, stroke, peripheral neuropathy, muscle diseases, hydrocephalus, cognitive impairment, etc. (3) Accompanied by vital organ (heart, lung, liver, kidney, etc.) failure, malignant tumors, unstable conditions and other serious medical diseases. (4) Those who have serious behavior problems or mental confusion. (5)Those who do not cooperate with the examination.
Minimum Eligible Age

40 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fujian Medical University Union Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Guoen Cai

Role: CONTACT

0591-18120922978

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2023YF062-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.